Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 9;68(7):e0038124.
doi: 10.1128/aac.00381-24. Epub 2024 Jun 12.

In vitro activity of taurolidine against clinical Candida auris isolates: relevance to catheter-related bloodstream infections

Bruce E Reidenberg  1 , Stephen G Jenkins  2   3 , Jared L Crandon  4 , Elizabeth Hurlburt  4 , Xing Tan  4 , Paul R Rhomberg  5 , S J Ryan Arends  5 , Antony Pfaffle  4
Affiliations

In vitro activity of taurolidine against clinical Candida auris isolates: relevance to catheter-related bloodstream infections

Bruce E Reidenberg et al. Antimicrob Agents Chemother. .

Abstract

Candida auris is an evolving and concerning global threat. Of particular concern are bloodstream infections related to central venous catheters. We evaluated the activity of taurolidine, a broad-spectrum antimicrobial in catheter lock solutions, against 106 C. auris isolates. Taurolidine was highly active with a MIC50/MIC90 of 512/512 mg/L, over 20-fold lower than lock solution concentrations of ≥13,500 mg/L. Our data demonstrate a theoretical basis for taurolidine-based lock solutions for prevention of C. auris catheter-associated infections.

Keywords: CLABSI; Candida auris; catheter-related bloodstream infection; taurolidine.

PubMed Disclaimer

Conflict of interest statement

J.L.C., E.H., X.T., and A.P. are all employees of CorMedix Inc.; B.E.R. is a consultant to CorMedix Inc.

Similar articles

See all similar articles

References

    1. CDC . 2019. Antibiotic resistance threats in the United States, 2019. U.S. Department of Health and Human Services, CDC, Atlanta, GA.
    1. WHO fungal priority pathogens list to guide research, development and public health action. 2022. Geneva: World Health Organization
    1. Jacobs SE, Jacobs JL, Dennis EK, Taimur S, Rana M, Patel D, Gitman M, Patel G, Schaefer S, Iyer K, Moon J, Adams V, Lerner P, Walsh TJ, Zhu Y, Anower MR, Vaidya MM, Chaturvedi S, Chaturvedi V. 2022. Candida auris pan-drug-resistant to four classes of antifungal agents. Antimicrob Agents Chemother 66:e0005322. doi:10.1128/aac.00053-22 - DOI - PMC - PubMed
    1. Biagi MJ, Wiederhold NP, Gibas C, Wickes BL, Lozano V, Bleasdale SC, Danziger L. 2019. Development of high-level echinocandin resistance in a patient with recurrent Candida auris candidemia secondary to chronic candiduria. Open Forum Infect Dis 6:ofz262. doi:10.1093/ofid/ofz262 - DOI - PMC - PubMed
    1. Briano F, Magnasco L, Sepulcri C, Dettori S, Dentone C, Mikulska M, Ball L, Vena A, Robba C, Patroniti N, Brunetti I, Gratarola A, D’Angelo R, Di Pilato V, Coppo E, Marchese A, Pelosi P, Giacobbe DR, Bassetti M. 2022. Candida auris candidemia in critically ill, colonized patients: cumulative incidence and risk factors. Infect Dis Ther 11:1149–1160. doi:10.1007/s40121-022-00625-9 - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources